<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">Antiphospholipid syndrome</z:e> (APS) is an <z:hpo ids='HP_0002960'>autoimmune disease</z:hpo> that is characterized by <z:mp ids='MP_0005048'>thrombosis</z:mp>, recurrent fetal loss and <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0003613'>Antiphospholipid antibodies</z:hpo>, detected by enzyme-linked immunoabsorbent assays (aCL) and/or in vitro blood clotting assays (LAC) are strongly associated with APS </plain></SENT>
<SENT sid="2" pm="."><plain>Both the <z:chebi fb="22" ids="24431">molecular structures</z:chebi> used by pathogenic <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> and the genetic mechanisms leading to their production are unknown </plain></SENT>
<SENT sid="3" pm="."><plain>We describe here the variable region genes of seven IgG <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> derived from two APS patients </plain></SENT>
<SENT sid="4" pm="."><plain>Of these, five are pathogenic as defined in a mouse model of <z:mp ids='MP_0005048'>thrombosis</z:mp> and two are not </plain></SENT>
<SENT sid="5" pm="."><plain>Analyses of the expressed variable region genes show no preferential V gene usage </plain></SENT>
<SENT sid="6" pm="."><plain>However, similar to anti-DNA antibodies, pathogenic <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> contain an increased number of <z:chebi fb="0" ids="32700">arginine residues</z:chebi> in the third complimentarity-determining region (CDR3) of their H chains </plain></SENT>
<SENT sid="7" pm="."><plain>The increased accumulation of <z:chebi fb="0" ids="32700">arginine residues</z:chebi> in the V(H) CDR3 may act to enhance antigen binding, promote disease and point to the importance of the H chain in the pathogenic potential of certain <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> </plain></SENT>
</text></document>